
This Spectacular Vanguard ETF Is on Course to Crush the S&P 500 Yet Again in 2025
Eleven sectors are represented in the S&P 500, but information technology is the largest by a country mile.
Investors who haven't owned tech stocks like Nvidia, Microsoft, and Apple over the past decade have likely underperformed the broader market.
The Vanguard Information Technology ETF offers investors exposure to those stocks, and over 300 others from this high-flying sector.
10 stocks we like better than Vanguard Information Technology ETF ›
Information technology is the largest of 11 sectors in the S&P 500, with a weighting of 33.9%. That's partly because the sector is home to the world's three most valuable companies: Nvidia, Microsoft, and Apple, which have a combined market capitalization of $11 trillion.
They have each obliterated the return of the S&P 500 over the past decade:
NVDA data by YCharts
Investors who haven't owned those three tech titans have probably underperformed the broader market. However, they aren't the only high-flying stocks in the information technology sector, and there's a simple way to buy them all.
The Vanguard Information Technology ETF (NYSEMKT: VGT) is an exchange-traded fund (ETF) that invests exclusively in information technology stocks. It outperformed the S&P 500 every year, on average, since it was established in 2004, and it's on track to do so again in 2025.
The world's most dominant tech stocks packed into one low-cost ETF
The Vanguard ETF isn't limited to the information technology stocks within the S&P 500 alone -- it invests across the entire sector. It holds 319 stocks from 12 \information technology subsegments including semiconductors, systems software, and application software.
The semiconductor segment is the largest by far with a weighting of 30.4%, which shouldn't be a surprise considering data center hardware is at the heart of the artificial intelligence (AI) boom. Nvidia's market capitalization recently topped $4.2 trillion because of the enormous demand for its data center chips, and even Broadcom has become a trillion-dollar giant thanks to its AI hardware sales.
But the AI theme is prevalent throughout the entire information technology sector. In fact, each of the top 10 holdings in the Vanguard ETF -- which represent 58.8% of the value of its portfolio -- is participating in the AI race.
Stock
Vanguard ETF Portfolio Weighting
1. Nvidia
16.74%
2. Microsoft
14.89%
3. Apple
13.03%
4. Broadcom
4.57%
5. Oracle
2.05%
6. Palantir Technologies
1.64%
7. Cisco Systems
1.58%
8. International Business Machines
1.56%
9. Salesforce
1.47%
10. Advanced Micro Devices
1.31%
Data source: Vanguard. Portfolio weightings are accurate as of June 30, 2025, and are subject to change.
Microsoft and Oracle are two of Nvidia's biggest customers. They operate a growing number of data centers fitted with thousands of AI chips, and they rent the computing capacity to businesses and developers for profit. Microsoft, however, has also become a leader in AI software thanks to its Copilot virtual assistant, which is integrated into each of its most popular products including Windows and 365 (Word, Excel, and PowerPoint).
Palantir is another AI software powerhouse. It operates three core platforms: Gotham and Foundry help businesses and governments extract actionable insights from their data, and AIP (Artificial Intelligence Platform) helps them integrate AI into their everyday workflows. Prominent tech analyst Dan Ives from Wedbush Securities believes Palantir's valuation could soar by 177% to reach $1 trillion within the next three years, as enterprises race to turn their data into dollars.
Outside of its top 10 holdings, the Vanguard ETF holds a number of other prominent AI software stocks. They include AI cybersecurity giants Palo Alto Networks and CrowdStrike, plus Adobe, and Snowflake, to name just a few.
The best part about the Vanguard ETF might be its ultra-low cost. It has an expense ratio of just 0.09%, so a $10,000 investment would incur an annual fee of just $9. Vanguard says competing funds across the industry charge an average of 0.93%, so they are a whopping 10 times more expensive to own.
On course to beat the S&P 500 again in 2025
The Vanguard Information Technology ETF generated a compound annual return of 13.7% since its inception in 2004, handily beating the S&P 500 which has returned an average of 10.1% per year over the same period.
That trend looks set to continue in 2025, because the ETF was sitting on a year-to-date gain of 10.3% as of market close July 18, whereas the S&P was sitting on a lesser gain of 7.3%. Tech stocks are having yet another stellar year thanks to AI, with shares of Microsoft, Nvidia, and Palantir up 21%, 24%, and 104%, respectively.
But investors should never put all of their eggs in one basket. If the AI boom falters, those high-flying stocks could suffer steep corrections which might lead the information technology sector to temporarily underperform the rest of the market. As a result, this Vanguard ETF should only be added to a diversified portfolio to mitigate risk.
That strategy can still drive incredible returns if things go well. An investor who placed $20,000 in the S&P 500 in 2004 would be sitting on $167,000 today. But had they split the $20,000 equally and placed $10,000 in the S&P 500 and $10,000 in the Vanguard ETF, they would have $264,800 today. That's a life-changing difference for most people.
Should you invest $1,000 in Vanguard Information Technology ETF right now?
Before you buy stock in Vanguard Information Technology ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard Information Technology ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $665,092!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,477!*
Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
11 minutes ago
- Globe and Mail
COIN to Report Q2 Earnings: Will Higher Trading Volume Fuel Growth?
Coinbase Global COIN is set to report second-quarter 2025 results on July 31, after market close. This company beat estimates in three of the last four reported quarters and matched in one. Let's discuss the factors that are likely to be reflected in the upcoming quarterly results. Trading volume in the second quarter is likely to have improved owing to increased asset volatility and improved crypto asset prices. Crypto trading remains a major revenue driver for COIN. It has been prioritizing crypto utility by investing in infrastructure and foundational platforms. Increased market share in the U.S. spot and derivatives markets and an expanded product portfolio and international market presence are likely to have added to the upside. The company is likely to have benefited from the acquisition of Deribit, the world's leading crypto options exchange, in the quarter. This makes Coinbase the leading crypto derivative platform globally by open interest. The Zacks Consensus Estimate for total trading volume is pegged at 249 million, indicating an improvement of 10.1% from the year-ago reported number. The consensus estimate for total volume - Consumer is pegged at 46.1 million, suggesting a 25% increase from the year-ago reported number. The consensus mark for total volume - Institution is pegged at 203 million, indicating a surge of 7.4% from the year-ago reported number. Transaction revenues are likely to have benefited from higher fees for Consumer and Institutional. The Zacks Consensus Estimate for transaction revenues is pegged at $759 billion, indicating an increase of 23% from the year-ago reported figure. The Zacks Consensus Estimate for transaction revenues - Consumer is pegged at $647 million. The consensus estimate for transaction revenues - Institutional is pegged at $54 million. Revenues are likely to have benefited from market share gains in U.S. spot and derivatives trading, along with increased volumes in custody, staking and USDC assets, as well as growth in Coinbase One subscriptions. What Our Quantitative Model Predicts Our proven model predicts an earnings beat for Coinbase this time around. This is because the stock has the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), which increases the odds of an earnings beat. Earnings ESP: Coinbase's Earnings ESP is +12.05%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Coinbase currently has a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here. Other Stocks to Consider Euronet Worldwide EEFT has an Earnings ESP of +2.53% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $2.63 per share, indicating an increase of 16.9% from the year-ago reported figure. EEFT's earnings beat estimates in only one of the last four quarters, met in two and missed in one. Houlihan Lokey HLI has an Earnings ESP of +0.99% and carries a Zacks Rank of 3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $1.69, indicating a surge of 38.5% from the year-ago reported figure. HLI's earnings beat estimates in three of the last four quarters, while missing in one. Inter & Co. Inc. INTR has an Earnings ESP of +5.41% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 12 cents per share, indicating an increase of 33% from the year-ago reported figure. INTR's earnings beat estimates in two of the last four quarters, met in one and missed in one. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Euronet Worldwide, Inc. (EEFT): Free Stock Analysis Report Houlihan Lokey, Inc. (HLI): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis Report Inter & Co. Inc. (INTR): Free Stock Analysis Report This article originally published on Zacks Investment Research (


Globe and Mail
11 minutes ago
- Globe and Mail
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation. Univest, LLC acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes. The shares of Series A-3 Preferred Stock were offered and issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D under the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares of Series A-3 Preferred Stock and the underlying shares of common stock may not be offered or sold in the United States unless registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series A-3 Preferred Stock within 45 days after the closing date. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The Company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders. For more information about Qualigen Therapeutics, Inc., please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, assumptions, and projections about future events and involve inherent risks and uncertainties. These forward-looking statements include, but are not limited to, statements the filing of a resale registration statement, and the Company's future business plans and strategies. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'could,' 'would,' 'should,' 'continues,' and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from those projected due to a number of factors, including risks related to the Company's ability to successfully develop and commercialize its product candidates, regulatory developments, market conditions, the Company's ability to maintain compliance with Nasdaq listing requirements, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Globe and Mail
11 minutes ago
- Globe and Mail
Securities Fraud Investigation Into Charter Communications, Inc. (CHTR) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Charter Communications, Inc. ('Charter' or the 'Company') (NASDAQ: CHTR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHARTER COMMUNICATIONS, INC. (CHTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024. The Company's total video customers also decreased by 80,000. On this news, Charter's stock price fell $70.25, or 18.5%, to close at $309.75 per share on July 25, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Charter securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.